Search

Manufacturers produce pharmaceutical products with patients in mind that is; these products are developed for patients to use to treat their diseases and illness so that they can get better or healed. Manufacturers, policy makers and healthcare professionals are to be aware of these factors to ensure an effective uptake of pharmaceutical products developed by manufacturers. [Extracted from the article]

Market access (MA) and health economics and outcomes research professionals (HEOR) work with patients to ensure effective uptake of pharmaceutical products. Conclusions The findings from this study showed that MA and HEOR professionals do have a role in the uptake of pharmaceutical products by patients. [Extracted from the article]

Approximately 20 - 50 million people sustain nonfatal injuries as a result of road traffic accidents (RTA). The study reviewed the economic burden of musculoskeletal (MSK) disorders caused from RTA in low and middle-income countries (LMICs). [Extracted from the article]

This study examined the views of Market Access Professionals in terms of barriers to ensuring effective uptake of pharmaceutical products by patients. The study identified that MA professionals considered that there were barriers to ensuring effective uptake of pharmaceutical products by patients. [Extracted from the article]

Pharmaceutical products are developed mainly with patients/end-users in mind. The responses to the second question were; identification of need for the product 199 (26.3%), efficacy 148 (19.6%), ensuring safety 96 (12.7%), patients awareness/education 214 (28.3%), and ensuring the product is available 99 (13.1%). [Extracted from the article]

Evidence suggests that payers should be involved in early stage of pharmaceutical products development to ensure smooth access to pharmaceutical products. Payers' perspective should be incorporated into evidence generation for pricing, reimbursement and decision-making by Health Technology Assessment (HTA) bodies. Participants were asked how to resolve payers' related issues arising from Target Product Profile (TPP), Product Development Plan (PDP) and Design of Clinical Trials (DOCT). [Extracted from the article]

Pre-launch stage of pharmaceutical product development consists of 3 components; Target Product Profile (TPP), Product Development Plan (PDP) and Design of Clinical Trials (DOCT). Stakeholders are to work on evidence generation requirements at DOCT level, and should focus on payers' issues at PDP level and at TPP level. [Extracted from the article]

Market Access (MA) and Health Economic/Outcomes Research (HEOR) activities aim to ensure patients get the right pharmaceutical product(s) at the right time and price to ensure cost-effectiveness of interventions. Participants included were professionals with an MA/HEOR background attending the International Society for Pharmaco-economics and Outcomes Research (ISPOR) at Barcelona 2018. [Extracted from the article]

Payers are to be involved in the development of pharmaceutical products since they pay or reimburse these products. The study investigated how involved payers should be in early stage of pharmaceutical product development i.e. Target Product Profile (TPP), Product Development Plan (PDP) and Design of Clinical Trials (DOCT). [Extracted from the article]

The definition of Market Access (MA) has not been clearly documented and when documented is not clear as each participants tend to define MA based on the activities carried out by their MA team. Hence, MA can be defined based on this study as patients having access to the right drug at the right price through effective working with stakeholders to ensure that pharmaceutical products are reimbursed. [Extracted from the article]

This systematic review examined the cost-effectiveness of personalisation-home care interventions compared with nursing home care. Future studies are required to examine the cost-effectiveness of home care/personalisation compared to nursing home care, especially in Europe, from health and social care, and caregivers perspectives. [Extracted from the article]

In the management of total knee and or hip replacement (TKHR), the long- term effectiveness of physiotherapy interventions may slowly accumulate over a period. This study reviewed the long-term cost- effectiveness (CE) of physiotherapy interventions for patients with TKHR. [Extracted from the article]

Low-back pain (LBP) is a major public health problem globally and its direct and indirect healthcare costs are growing rapidly. The aim of this study was to assess the cost-effectiveness of Virtual Reality Game (VRG) compared to Clinic-based McKenzie therapy (CBMT) for chronic non-specific LBP. Conclusion The findings of this study suggests that VRG was cost saving for chronic non-specific LBP compared to CBMT. [Extracted from the article]

Physiotherapy interventions for musculoskeletal disorders (MSDs) are diverse. This study investigated the effect of physiotherapy interventions on pain in patients with MSDs in a real-world setting. Physiotherapy interventions were useful in reducing pain intensity in patients with MSDs in the real-world. [Extracted from the article]